Lungenkarzinome

Prof. Michael Thomas

Rothschild S et al. SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial.
Wu YL et al. CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation – Final overall survival analysis of the randomized phase III trial 1 analysis of the randomized phase III trial.
Herbst RS et al. Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

Prof. Stefan Rieken

Jabbour SK et al. Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.

Dr. Niels Reinmuth

Maemondo M et al. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
Rotow JK et al. Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC). /li>
Wang X et al. First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).
Piper-Vallillo A et al. High-dose osimertinib for CNS progression in EGFR+ non-small cell lung cancer (NSCLC): A multi-institutional experience.

Dr. Sebastian Michels

Binkley MS et al. KEAP1/NFE2L2 mutations to predict local recurrence after radiotherapy but not surgery in localized non-small cell lung cancer.
Tamiya Y et al. Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS–mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).
Awad MM et al. Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms.
Nishio K et al. RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).

Lungenkarzinome Highlight

404 Not Found

Die Seite wurde leider nicht gefunden

Gründe dafür könnten sein, dass Sie eine falsche oder veraltete URL aufgerufen haben. Oder aber die Seite wurde von uns umbenannt, verschoben und archiviert. Versuchen Sie es noch einmal und aktualisieren Sie die Seite.

Andernfalls verwenden Sie bitte den folgenden Link, um die von Ihnen gewünschten Inhalte zu finden

Zur Startseite